NasdaqGS:AMGNBiotechs
Amgen (AMGN) Stock Looks Reasonable On Earnings While Cash Flow Stays Strong
Amgen stock has delivered a 75.2% return over the past five years, and the current valuation picture sits in a middle ground where the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market based multiples look roughly in line with peers.
Over five years, a 75.2% total return suggests Amgen has already rewarded patient shareholders, so any further upside case now leans more on valuation support than on a low entry price.
Future cash flow expectations...